CD40- and 41BB-specific antibody fusion proteins with PDL1 blockade-restricted agonism

Background: A strategy to broaden the applicability of checkpoint inhibitors is the combined use with antibodies targeting the immune stimulatory receptors CD40 and 41BB. However, the use of anti-CD40 and anti-41BB antibodies as agonists is problematic in two ways. First, anti-CD40 and anti-41BB ant...

Descripción completa

Detalles Bibliográficos
Autores principales: Medler, Juliane, Kucka, Kirstin, Melo, Vinicio, Zhang, Tengyu, von Rotenhan, Stefan, Ulrich, Jakob, Bremer, Edwin, Hudecek, Michael, Beilhack, Andreas, Wajant, Harald
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2022
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8825603/
https://www.ncbi.nlm.nih.gov/pubmed/35198053
http://dx.doi.org/10.7150/thno.66119

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8825603/
https://www.ncbi.nlm.nih.gov/pubmed/35198053
http://dx.doi.org/10.7150/thno.66119

Ejemplares similares